The Economic Benefit of Remission for Patients with Rheumatoid Arthritis
ConclusionsCost of care increased with increasing DA state, with patients in remission having the lowest costs. Optimizing DA has the potential for substantial savings in healthcare costs, although may be partially offset by the high cost of targeted RA therapies. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - July 14, 2022 Category: Rheumatology Source Type: research
Publisher Correction to: Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2)
(Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - July 2, 2022 Category: Rheumatology Source Type: research
A Randomized Pharmacokinetic Study in Healthy Male Subjects Comparing a High-concentration, Citrate-free SB5 Formulation (40 mg/0.4 ml) and Prior SB5 (Adalimumab Biosimilar)
ConclusionsThis bridging study demonstrated PK equivalence and comparable safety and tolerability of subcutaneous injection of SB5 via SB5-HC or SB5-LC.Clinicaltrials.gov identifierhttps://clinicaltrials.gov/ct2/show/NCT04514796. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - July 1, 2022 Category: Rheumatology Source Type: research
Efficacy of Abatacept Versus Tumor Necrosis Factor Inhibitors in Anti-citrullinated Protein Antibody-Positive Patients with Rheumatoid Arthritis: Results from a Korean Nationwide Biologics Registry
ConclusionsThis real-world study suggests that abatacept may have better clinical response compared to TNFi in patients with established ACPA-positive RA, especially in those that were biologics-na ïve. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - June 18, 2022 Category: Rheumatology Source Type: research
Letter to the Editor Regarding Esophageal Dysfunction and Systemic Sclerosis: Drugs Should be Kept in Mind
(Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - June 18, 2022 Category: Rheumatology Source Type: research
A Response to: Letter to the Editor Regarding [Esophageal Dysfunction and Systemic Sclerosis: Drugs Should be Kept in Mind]
(Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - June 18, 2022 Category: Rheumatology Source Type: research
Dactylitis and Early Onset Psoriasis in Psoriatic Arthritis: Are they Markers of Disease Severity? A Clinical Study
ConclusionsThere are some clinical and therapeutic differences in PsA patients linked to the PsO onset age, namely dactylitis in EOP. Other characteristics found were: a “comorbidities trend” in LOP patients and a more frequent use of anti-IL17 in EOP. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - June 17, 2022 Category: Rheumatology Source Type: research
Plasma Exchange in a Patient with Immune Thrombocytopenia Associated with Antiphospholipid Syndrome Hospitalized for COVID-19
AbstractThrombocytopenia is a common feature of antiphospholipid syndrome (APS) and rarely requires treatment. Here we present the case of a 71-year-old man hospitalized for severe immune thrombocytopenia (ITP) secondary to APS and concomitant SARS-CoV-2 infection. The patient was successfully treated with systemic corticosteroids, intravenous immunoglobulins, and plasma exchange (PEX). Few data are published on the use of plasma exchange in the treatment of thrombocytopenia in non-catastrophic APS. In the setting of acute infection when immunosuppressive therapies might be contraindicated, plasma exchange may be considere...
Source: Rheumatology and Therapy - June 15, 2022 Category: Rheumatology Source Type: research
Letter to the Editor Regarding “Colchicine Against SARS-CoV-2 Infection: What is the Evidence?”
(Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - June 13, 2022 Category: Rheumatology Source Type: research
Interim 2-Year Analysis from SERENA: A Real-World Study in Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Secukinumab
ConclusionsAfter more than 2 years since initiation, secukinumab demonstrated high retention rates and favorable safety profile as well as sustained effectiveness in patients who continued secukinumab treatment. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - June 8, 2022 Category: Rheumatology Source Type: research
Health Economic Evaluation of a High and Low Molecular Weight Hyaluronic Acid Formulation for the Treatment of Knee Osteoarthritis. Post Hoc Analyses from a Randomized Clinical Trial
ConclusionsThese results confirm the role of HA –HL as a cost-effective therapeutic option in the management of OA. However, more studies taking into account the utilization of other health care resources are needed. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - June 3, 2022 Category: Rheumatology Source Type: research
The Non-medical Switch from Reference Adalimumab to Biosimilar Adalimumab is Highly Successful in a Large Cohort of Patients with Stable Inflammatory Rheumatic Joint Diseases: A Real-Life Observational Study
ConclusionsIn line with earlier reports, the transition to ADAbio went successful in the majority of patients with stable inflammatory rheumatic joint diseases. Patient-reported symptoms without objective signs that indicate a flare of disease activity after the switch to ADAbio are probably explained by nocebo effects. A pre-emptive approach to counteract nocebo effects and stimulate placebo response may have a positive impact on health outcomes for patients and preserve the economic benefits of cost savings that can be achieved by prescribing a biosimilar instead of the reference drug. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - June 3, 2022 Category: Rheumatology Source Type: research
Correction to: Real-world Treatment Patterns and Clinical Outcomes of Baricitinib in Rheumatoid Arthritis patients in Spain: Results of a multicenter, observational study in routine clinical practice (The ORBIT-RA Study)
(Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - June 2, 2022 Category: Rheumatology Source Type: research
A Response to: Letter to the Editor Regarding the Article: “Colchicine Against SARS-CoV-2 Infection: What is the Evidence?”
(Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - May 27, 2022 Category: Rheumatology Source Type: research
Clinical Characteristics of Potential “Difficult-to-treat” Patients with Psoriatic Arthritis: A Retrospective Analysis of a Longitudinal Cohort
ConclusionsOur study firstly evaluated the presence of clinical characteristics of potential D2T patients and may contribute to future research on this intriguing aspect. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - May 25, 2022 Category: Rheumatology Source Type: research
